Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and Masimo's claims are rejected in court. Apple and medical equipment maker ...

Unrecognized Contract Revenues: $1.65 billion as of the end of Q3. Masimo Corp (NASDAQ:MASI) reported healthcare revenues of $343 million for the third quarter, representing a 12% growth compared ...

Apple convinced a federal jury on Friday that early versions of health monitoring tech company Masimo's smartwatches ... which is worth about $3.5 trillion, just $250 in damages - the statutory ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside. The below comparison of the analyst ratings ...

Masimo MASI2.20%increase; green up pointing triangle said Joe Kiani, who previously informed the board of his decision to resign as chief executive, has been terminated by the company. Kiani’s ...

In this article, we are going to take a look at where Masimo Corporation (NASDAQ ... increase at a compound annual growth rate (CAGR) of 5.8% from 2023 to 2032, reaching over $996.93 billion.

The FDA has only approved one medical wearable that provides continuous oxygen saturation (SpO2) and pulse rate tracking: the Masimo W1 Medical watch. “If you really want a wearable that’s ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside. Analyzing Ratings Among Peers The below ...

IRVINE, California - Masimo (NASDAQ:MASI) Corporation (NASDAQ:MASI) reported third-quarter earnings that beat analyst expectations, but its shares tumbled 7.5% as fourth-quarter revenue guidance ...